Home \ Antibodies \ Properdin, Mouse, mAb E12
Catalog # HM1138

Properdin, Mouse, mAb E12

Please choose the quantity of items you wish to add to your cart…
Find distributor

Monoclonal antibody E12 recognizes mouse properdin. The complement system is the first line of defense against pathogens and facilitates elimination of apoptotic and damaged cells. Positive regulator plasma protein properdin is critical for the alternative pathway of complement. It is a single-chain glycoprotein (ca 53kDa) consisting of six TSR sequences. In the blood it exists as a mixture of preferably head-to-tail trimers, but also dimers and tetramers. The protein is produced by leukocytes, like activated neutrophils monocytes and T-lymphocytes, but also by eg. stressed endothelial cells.
Properdin can both initiate and positively regulate the alternative pathway activity together with C3 and factors B, D, I and H. It binds to C3b where It stabilizes the labile C3bBb convertase which is deposited on immune complexes or foreign surfaces. Thereby enhancing the AP by stimulation of amplification of C3bBb-convertase formation in competition with catabolism of C3b by factor I, which uses factor H as a cofactor. The local amplification process leads to the creation of the alternative pathway C5 convertase, C3bBb3b, and initiates the terminal pathway of complement activation. The alternative pathway may account for ca 80% of the terminal pathway activity. Properdin has also been shown to directly limit factor H activity.
Recent studies show that properdin is also a pattern-recognition receptor (PRR) able to bind directly to microbial surfaces, apoptotic and necrotic cells (dangerous nonself and altered self). Inappropriate activation or dysregulation of the alternative pathway is a critical factor in development of several autoimmune conditions. Targets opsonized with properdin are labeled for clearance by scavenger cells, even without complement. This makes it a potential therapeutic target in diseases. Recent studies has shown renewed interest in the evaluating role of properdin in disease pathogenesis, like Asthma, arthritis, septic shock, AMD and C3 glomerulopathy.

Functional studies, Immuno assays, Western blot

Application Notes
W: A reduced sample treatment and SDS-Page was used. The band size for native properdin is ~52 kDa and the antibody recognizes recombinant TSR5/6 antigen which has a band size of ~18 kDa (Ref.1).
IA: Antibody E12 can be used as capture and detection antibody.
FS: Antibody E12 abrogated alternative pathway activity and full inhibitory activity lasted at least 14 days (Ref.1).

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
100 µg, 20 µg
0.2 ml (100 μg/ml) 0.2 μm protein G purified antibody solution in PBS.
Recombinant his-tagged mTSR5/6 isolated from E.coli (refolded)
Armenian hamster IgG
Complement factor P<br> - Gene name: Cfp, Pfc
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Autoimmunity, Infectious diseases, Nephrology
CoA-TDS HM1067-HM2099 Safety Data Sheet

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us